loading
Biodol Therapeutics, a pharmaceutical company, aims at developing first-in-class compounds
for the specific treatment of chronic neuropathic pain.
Learn more
The NP Market
At least
0
MILLION PEOPLE
currently affected in USA, EU5 and Japan
More than
0
BILLION US$
pharmaceutical market for USA, EU5 and Japan
Less than
0
% OF PATIENTS
achieve a reduction of more than 30% of the pain
Around
0
BILLION $ PER YEAR
of global economic cost in the USA and Europe
NP syndromes currently affect ca. 35 million people in the USA, EU Top5 and Japan for an estimated market size of more than US$ 6 billion.

During the next years, due to the loss of market exclusivity for the 3 leader products (50% of the market share), and in case of the absence of game-changing therapies with no emerging specific NP-treatment, the overall NP market is expected to remain relatively flat.

Nevertheless, underlying key market drivers will definitely support long-term growth rates: i) change in population size and increasing prevalence of metabolic syndrome-induced diabetes, ii) population ageing and rising prevalence of infectious and degenerative joint diseases, iii) increasing patients with cancer, iv) increasing HIV/AIDS population, v) improved diagnosis and treatment access.

The medical challenge is to treat these patients with efficient drugs addressing the cause and not the consequences of the disease, while avoiding the adverse effects of actual non-specific treatments (somnolence, constipation, dry mouth, nausea, dizziness, weight gain, vomiting, tiredness, itch, local irritation, local pain, oedema, erythema, etc.).

This situation is of course disastrous for the well-being of affected people (provoking depression, sleep disorders, hospitalization, absenteeism) and extremely costly to our society. The global economic cost of chronic pain diseases was recently approximated to US$150-200 billion per year in the U.S.A. and Europe, which is more than cardiovascular diseases and cancer together.

By its deeper understanding of biochemical signalling pathways of the disease, Biodol Therapeutics is the perfect opportunity to design the future first specific NP-treatment.
The Team
Biodol Therapeutics was set up by an experienced and dynamic team with complementary scientific and working experiences and has set up a Scientific Advisory Board with partners and appropriate key opinion leaders.
Fabien GRANIER
PhD in Quantum Chemistry
Chief Executive Officer
Jean VALMIER
MD, PhD in Neuroscience
Principal Scientific Advisor. Professor at Montpellier University and at the Institut des Neurosciences of Montpellier
Pierre SOKOLOFF
PhD in Molecular Pharmacology
Chairman of Biodol Therapeutics Scientific Advisory Board. Former Head of CNS exploratory R&D – Pierre Fabre Institute
Didier ROGNAN
Pharmacist, PhD in Medicinal Chemistry
Scientific Advisor. CNRS Research Director
Bernard PAU
PhD in Immunology
Business Development. Former Director of the Department of Life Sciences of the CNRS.
2016 © Biodol. All rights reserved.